AV 0113

Drug Profile

AV 0113

Alternative Names: AV0113; Cancer vaccine - Activartis; Cancer vaccine - Trimed; Dendritic cell vaccine - Activartis; Trivax cancer vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trimed Biotech
  • Developer Activartis Biotech
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes - Brain cancer

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Prostate-cancer in Austria (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Sarcoma in Austria (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In children, Late-stage disease) in Austria (Intralymphatic, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top